My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 610 / DOI: 10.3332/ecancer.2016.610

Clinical Study

Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent

Diclofenac (DCF) is a well-known and widely used non-steroidal anti-inflammatory drug (NSAID), with a range of actions which are of interest in an oncological context. While there has long been an interest in the use of NSAIDs in chemoprevention, there is now emerging evidence that such drugs may have activity in a treatment setting. DCF, which is a potent inhibitor of COX-2 and prostaglandin E2 synthesis, displays a range of effects on the immune system, the angiogenic cascade, chemo- and radio-sensitivity and tumour metabolism. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. Based on this evidence the case is made for further clinical investigation of the anticancer effects of DCF, particularly in combination with other agents - with a range of possible multi-drug and multi-modality combinations outlined in the supplementary materials accompanying the main paper.

Keywords: Drug repurposing, diclofenac, NSAID, perioperative intervention, ReDO project

Loading Article Metrics ... Please wait

Related articles

Conference Report: Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai

Abstract | Full Article | PDF Published: 02 Nov 2016 / DOI: 10.3332/ecancer.2016.689

Special Issue: The cost of cancer care is not related to its outcomes

Abstract | Full Article | PDF Published: 28 Oct 2016 / DOI: 10.3332/ecancer.2016.687

Special Issue: Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology

Abstract | Full Article | PDF Published: 28 Oct 2016 / DOI: 10.3332/ecancer.2016.686

Special Issue: Health technology assessment and value: the cancer value label (CAVALA) methodology

Abstract | Full Article | PDF Published: 28 Oct 2016 / DOI: 10.3332/ecancer.2016.685

Special Issue: Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis

Abstract | Full Article | PDF Published: 28 Oct 2016 / DOI: 10.3332/ecancer.2016.684



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence